Wednesday, July 8, 2026

Patent intelligence · US

US 11529390

PCSK9 inhibitory polypolypeptides and methods of use

granted A61KA61K38/16A61K38/55A61K47/6937
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 15
Patent details — US 11529390
Jurisdiction
US
Status
granted
Grant date
Dec 20, 2022
Expiration
Dec 15, 2042
Claims
13
CPC classes
A61K, A61K38/16, A61K38/55, A61K47/6937
View on Google Patents ↗

Quick answer

US 11529390 (PCSK9 inhibitory polypolypeptides and methods of use) is held by INSTITUT DE CARDIOLOGIE DE MONTREAL. Status: granted. Granted Dec 20, 2022. Expires Dec 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
13
CPC classes
A61K, A61K38/16, A61K38/55, A61K47/6937

More from INSTITUT DE CARDIOLOGIE DE MONTREAL

Related pharmaceutical patents in our USPTO index.

  1. US 12419888

    Methods of treating elevated plasma cholesterol

    INSTITUT DE CARDIOLOGIE DE MONTREAL · Expires Sep 18, 2045

    granted
  2. US 11844771

    Methods of treating acute respiratory distress syndrome using colchicine

    INSTITUT DE CARDIOLOGIE DE MONTREAL · Expires Dec 14, 2043

    granted
  3. US 11795434

    Engineered stem cells and cellular products produced and secreted by such cells, methods of preparing, and uses thereof

    L'Institut de Cardiologie de Montréal · Expires Oct 19, 2043

    granted
  4. US 11639490

    Device and method for producing and purifying exosomes

    Foundation for Cardiological Research and Education (FCRE) · Expires Apr 27, 2043

    granted
  5. US 11400063

    Early administration of low-dose colchicine after myocardial infarction

    INSTITUT DE CARDIOLOGIE DE MONTREAL · Expires Jul 28, 2042

    granted
  6. US 10788490

    Dried cellulose-treated tissue for in-vitro complement activation assays and diagnostic kits

    ST. JUDE MEDICAL, CARDIOLOGY DIVISION, INC. · Expires Sep 24, 2040

    granted
  7. US 9789134

    Agent for the selective adjustment of blood lipids

    FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTION “RESEARCH INSTITUTE FOR CARDIOLOGY” · Expires Oct 12, 2037

    granted

Frequently asked questions

What is US patent 11529390?

US 11529390 (PCSK9 inhibitory polypolypeptides and methods of use) is held by INSTITUT DE CARDIOLOGIE DE MONTREAL. Status: granted. Granted Dec 20, 2022. Expires Dec 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11529390?

INSTITUT DE CARDIOLOGIE DE MONTREAL is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.

When does US 11529390 expire?

Our index shows an expiration date of Dec 15, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.